

Managing Asthma Long Term

Decision Variables

Impairment: Symptoms Rec_1: Cond_1: DV_1
Impairment: Nighttime awakenings Rec_1: Cond_1: DV_2
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB) Rec_1: Cond_1: DV_3
Interference with normal activity Rec_1: Cond_1: DV_4
Risk: Exacerbations requiring oral systemic corticosteroids Rec_1: Cond_1: DV_5
Impairment: Symptoms Rec_2: Cond_2: DV_6
Imapirment: Nighttime awakenings Rec_2: Cond_2: DV_7
Impairment: Interference with normal activity Rec_2: Cond_2: DV_8
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB) Rec_2: Cond_2: DV_9
Risk: Exacerbations requiring oral systemic corticosteroids Rec_2: Cond_2: DV_10
Risk: Treatment-related adverse effects Rec_2: Cond_2: DV_11
Impairment: Symptoms Rec_3: Cond_3: DV_12
Impairment: Nighttime awakenings Rec_3: Cond_3: DV_13
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB) Rec_3: Cond_3: DV_14
Impairment: Interference with normal activity

Rec_3: Cond_3: DV_15
Impairment: Lung function
Rec_3: Cond_3: DV_16
Risk: Exacerbations requiring oral systemic corticosteroids
Rec_3: Cond_3: DV_17
Intermittent
Rec_3: Cond_3: DV_18
Mild Persistent
Rec_3: Cond_3: DV_19
Moderate Persistent
Rec_3: Cond_3: DV_20
Severe Persistent
Rec_3: Cond_3: DV_21
Impairment: Symptoms
Rec_4: Cond_4: DV_22
Impairment: Nighttime awakenings
Rec_4: Cond_4: DV_23
Impairment: Interference with normal activity
Rec_4: Cond_4: DV_24
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB)
Rec_4: Cond_4: DV_25
Impairment: Lung function • FEV1 or peak flow • FEV1 /FVC
Rec_4: Cond_4: DV_26
Risk: Exacerbations requiring oral systemic corticosteroids
Rec_4: Cond_4: DV_27
Risk: Reduction in lung growth
Rec_4: Cond_4: DV_28
Risk: Treatment-related adverse effects
Rec_4: Cond_4: DV_29
Impairment: Symptoms
Rec_5: Cond_5: DV_30
Impairment: Nighttime awakenings

Rec_5: Cond_5: DV_31
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB)
Rec_5: Cond_5: DV_32
Impairment: Interference with normal activity
Rec_5: Cond_5: DV_33
Impairment: Lung function
Rec_5: Cond_5: DV_34
Risk: Exacerbations requiring oral systemic corticosteroids
Rec_5: Cond_5: DV_35
Impairment: Symptoms
Rec_6: Cond_6: DV_36
Impairment: Nighttime awakenings
Rec_6: Cond_6: DV_37
Impairment: Interference with normal activity
Rec_6: Cond_6: DV_38
Impairment: Short-acting beta2-agonist use for symptom control (not prevention of EIB)
Rec_6: Cond_6: DV_39
Impairment: FEV1 or peak flow
Rec_6: Cond_6: DV_40
Impairment: Validated questionnaires: ATAQ ACQ ACT
Rec_6: Cond_6: DV_41
Risk: Exacerbations requiring oral systemic corticosteroids
Rec_6: Cond_6: DV_42
Risk : Progressive loss of lung function
Rec_6: Cond_6: DV_43
Risk: Treatment-related adverse effects
Rec_6: Cond_6: DV_44